Although amorphous solid dispersions (ASDs) effectively increase bioavailability, tablet mass can be high due to the large fraction of excipients needed. This publication describes work to reduce the mass of an ASD tablet made from rapidly crystallizing drug with a low glass-transition temperature (Tg). A high-loaded dosage form (HLDF), made by strategically combining two polymers within the tablet, was used to reduce tablet mass by 40%. The resulting formulation had similar physical stability and in vitro performance as the benchmark formulation and exhibited excellent downstream manufacturability. To learn more, please read our publication.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center